Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
- Registration Number
- NCT02233881
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4222
Inclusion Criteria
- Patients of both gender older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
- Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion
Exclusion Criteria
- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic obstructive pulmonary disease patients Atrovent® - inhalets -
- Primary Outcome Measures
Name Time Method Change in the clinical picture after 4 weeks
- Secondary Outcome Measures
Name Time Method Assessment of efficacy by investigator on a 4-point scale after 4 weeks Assessment of efficacy by patient on a 4-point scale after 4 weeks Number of patients with adverse drug reactions up to 4 weeks Assessment of tolerability by patient on a 4-point scale after 4 weeks Assessment of tolerability by investigator on a 4-point scale after 4 weeks